Vor Biopharma director granted 56,549 stock options
Vor Biopharma Inc. director Fouad Namouni received a grant of stock options covering 56,549 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Vor Biopharma Inc. director Fouad Namouni received a grant of stock options covering 56,549 shares of common stock. The options have an exercise price of $14.0900 per share and expire on June 10, 2036. One thirty-sixth of the options will vest and become exercisable on July 11, 2026, with additional portions vesting monthly thereafter, contingent on his continued service. Following this grant, he holds 56,549 stock options directly.
Insider Trade Summary
Grant/Award: 56,549 shares
Grant/Award
1 txn
Insider
Namouni Fouad
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 56,549 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 56,549 contracts (Direct)
Footnotes (1)
- F1. One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.
Key Figures
Options granted: 56,549 options
Exercise price: $14.0900 per share
Expiration date: June 10, 2036
+3 more
6 metrics
Options granted
56,549 options
Stock Option (right to buy) grant to director
Exercise price
<money>$14.0900</money> per share
Strike price for Vor Biopharma common stock options
Expiration date
<date>June 10, 2036</date>
Option term end for granted stock options
Underlying shares
56,549 shares
Common stock underlying granted options
Vesting start date
<date>July 11, 2026</date>
First one-thirty-sixth of options vest
Post-grant option holdings
56,549 options
Total derivative holdings following transaction
Key Terms
Stock Option (right to buy), exercise price, vest and become exercisable, expiration date, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 14.0900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest and become exercisable financial
"shares subject to the option shall vest and become exercisable"
expiration date financial
"expiration_date: 2036-06-10T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Vor Biopharma (VOR) director Fouad Namouni report in this Form 4?
Fouad Namouni reported receiving a grant of stock options for 56,549 shares of Vor Biopharma common stock. These options are a compensation-related award, not an open-market purchase or sale of existing shares.
What is the exercise price of Fouad Namouni’s Vor Biopharma stock options?
The granted stock options have an exercise price of $14.0900 per share. This is the price at which he can buy Vor Biopharma common stock once the options vest and become exercisable over time.
How many Vor Biopharma options does Fouad Namouni hold after this grant?
After the transaction, Fouad Namouni holds 56,549 stock options directly. Each option relates to one share of Vor Biopharma common stock, reflecting his entire reported derivative position in this filing.
When do Fouad Namouni’s Vor Biopharma options start vesting?
The options begin vesting on July 11, 2026. One thirty-sixth of the grant vests on that date, with additional installments vesting each month, subject to his continued service with Vor Biopharma.
When do Fouad Namouni’s Vor Biopharma stock options expire?
The options expire on June 10, 2036. After that expiration date, any unexercised options will lapse and can no longer be used to purchase Vor Biopharma common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
